795 related articles for article (PubMed ID: 10215684)
1. Characterization of neuropeptide Y-induced feeding in mice: do Y1-Y6 receptor subtypes mediate feeding?
Iyengar S; Li DL; Simmons RM
J Pharmacol Exp Ther; 1999 May; 289(2):1031-40. PubMed ID: 10215684
[TBL] [Abstract][Full Text] [Related]
2. Evidence for involvement of neuropeptide Y receptors in the regulation of food intake: studies with Y1-selective antagonist BIBP3226.
Kask A; Rägo L; Harro J
Br J Pharmacol; 1998 Aug; 124(7):1507-15. PubMed ID: 9723965
[TBL] [Abstract][Full Text] [Related]
3. Receptor subtypes Y1 and Y5 are involved in the renal effects of neuropeptide Y.
Bischoff A; Avramidis P; Erdbrügger W; Münter K; Michel MC
Br J Pharmacol; 1997 Apr; 120(7):1335-43. PubMed ID: 9105710
[TBL] [Abstract][Full Text] [Related]
4. Role of the Y1 receptor in the regulation of neuropeptide Y-mediated feeding: comparison of wild-type, Y1 receptor-deficient, and Y5 receptor-deficient mice.
Kanatani A; Mashiko S; Murai N; Sugimoto N; Ito J; Fukuroda T; Fukami T; Morin N; MacNeil DJ; Van der Ploeg LH; Saga Y; Nishimura S; Ihara M
Endocrinology; 2000 Mar; 141(3):1011-6. PubMed ID: 10698177
[TBL] [Abstract][Full Text] [Related]
5. Orexigenic effect of the melanocortin MC4 receptor antagonist HS014 is inhibited only partially by neuropeptide Y Y1 receptor selective antagonists.
Kask A; Schiöth HB; Harro J; Wikberg JE; Rägo L
Can J Physiol Pharmacol; 2000 Feb; 78(2):143-9. PubMed ID: 10737677
[TBL] [Abstract][Full Text] [Related]
6. Subtype selectivity of the novel nonpeptide neuropeptide Y Y1 receptor antagonist BIBO 3304 and its effect on feeding in rodents.
Wieland HA; Engel W; Eberlein W; Rudolf K; Doods HN
Br J Pharmacol; 1998 Oct; 125(3):549-55. PubMed ID: 9806339
[TBL] [Abstract][Full Text] [Related]
7. L-152,804: orally active and selective neuropeptide Y Y5 receptor antagonist.
Kanatani A; Ishihara A; Iwaasa H; Nakamura K; Okamoto O; Hidaka M; Ito J; Fukuroda T; MacNeil DJ; Van der Ploeg LH; Ishii Y; Okabe T; Fukami T; Ihara M
Biochem Biophys Res Commun; 2000 May; 272(1):169-73. PubMed ID: 10872822
[TBL] [Abstract][Full Text] [Related]
8. Selective activation of central NPY Y1 vs. Y5 receptor elicits hyperinsulinemia via distinct mechanisms.
Gao J; Ghibaudi L; Hwa JJ
Am J Physiol Endocrinol Metab; 2004 Oct; 287(4):E706-11. PubMed ID: 15187000
[TBL] [Abstract][Full Text] [Related]
9. Molecular characterization of the ligand-receptor interaction of the neuropeptide Y family.
Cabrele C; Beck-Sickinger AG
J Pept Sci; 2000 Mar; 6(3):97-122. PubMed ID: 10759209
[TBL] [Abstract][Full Text] [Related]
10. Distribution of [Leu31,Pro34]NPY-sensitive, BIBP3226-insensitive [125I]PYY(3-36) binding sites in rat brain: possible relationship to Y5 NPY receptors.
Widdowson PS; Buckingham R; Williams G
Brain Res; 1997 Dec; 778(1):242-50. PubMed ID: 9462897
[TBL] [Abstract][Full Text] [Related]
11. The novel neuropeptide Y Y(1) receptor antagonist J-104870: a potent feeding suppressant with oral bioavailability.
Kanatani A; Kanno T; Ishihara A; Hata M; Sakuraba A; Tanaka T; Tsuchiya Y; Mase T; Fukuroda T; Fukami T; Ihara M
Biochem Biophys Res Commun; 1999 Dec; 266(1):88-91. PubMed ID: 10581170
[TBL] [Abstract][Full Text] [Related]
12. Evidence that the inhibition of luteinizing hormone secretion exerted by central administration of neuropeptide Y (NPY) in the rat is predominantly mediated by the NPY-Y5 receptor subtype.
Raposinho PD; Broqua P; Pierroz DD; Hayward A; Dumont Y; Quirion R; Junien JL; Aubert ML
Endocrinology; 1999 Sep; 140(9):4046-55. PubMed ID: 10465275
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological characterization of (125)I-1229U91 binding to Y1 and Y4 neuropeptide Y/Peptide YY receptors.
Schober DA; Gackenheimer SL; Heiman ML; Gehlert DR
J Pharmacol Exp Ther; 2000 Apr; 293(1):275-80. PubMed ID: 10734179
[TBL] [Abstract][Full Text] [Related]
14. Differential roles for neuropeptide Y Y1 and Y5 receptors in anxiety and sedation.
Sørensen G; Lindberg C; Wörtwein G; Bolwig TG; Woldbye DP
J Neurosci Res; 2004 Sep; 77(5):723-9. PubMed ID: 15352219
[TBL] [Abstract][Full Text] [Related]
15. Central NPY receptor-mediated alteration of heart rate dynamics in mice during expression of fear conditioned to an auditory cue.
Tovote P; Meyer M; Beck-Sickinger AG; von Hörsten S; Ove Ogren S; Spiess J; Stiedl O
Regul Pept; 2004 Aug; 120(1-3):205-14. PubMed ID: 15177939
[TBL] [Abstract][Full Text] [Related]
16. Co-expression of neuropeptide Y Y1 and Y5 receptors results in heterodimerization and altered functional properties.
Gehlert DR; Schober DA; Morin M; Berglund MM
Biochem Pharmacol; 2007 Dec; 74(11):1652-64. PubMed ID: 17897631
[TBL] [Abstract][Full Text] [Related]
17. Energy metabolic profile of mice after chronic activation of central NPY Y1, Y2, or Y5 receptors.
Henry M; Ghibaudi L; Gao J; Hwa JJ
Obes Res; 2005 Jan; 13(1):36-47. PubMed ID: 15761161
[TBL] [Abstract][Full Text] [Related]
18. Receptor subtypes Y1 and Y5 mediate neuropeptide Y induced feeding in the guinea-pig.
Lecklin A; Lundell I; Paananen L; Wikberg JE; Männistö PT; Larhammar D
Br J Pharmacol; 2002 Apr; 135(8):2029-37. PubMed ID: 11959807
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological evaluation of 1229U91, a novel high-affinity and selective neuropeptide Y-Y1 receptor antagonist.
Hegde SS; Bonhaus DW; Stanley W; Eglen RM; Moy TM; Loeb M; Shetty SG; DeSouza A; Krstenansky J
J Pharmacol Exp Ther; 1995 Dec; 275(3):1261-6. PubMed ID: 8531090
[TBL] [Abstract][Full Text] [Related]
20. Neuropeptide Y suppresses absence seizures in a genetic rat model primarily through effects on Y receptors.
Morris MJ; Gannan E; Stroud LM; Beck-Sickinger AG; O'Brien TJ
Eur J Neurosci; 2007 Feb; 25(4):1136-43. PubMed ID: 17331209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]